Aeterna Zentaris Announces At the Market Issuance Program - KFDA - NewsChannel 10 / Amarillo News, Weather, Sports

Aeterna Zentaris Announces At the Market Issuance Program

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Aeterna Zentaris Inc.

QUEBEC CITY, May 9, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") announced today that it has entered into an At Market Issuance ("ATM") Sales Agreement, dated May 9, 2014, with MLV & Co. LLC ("MLV"), under which the Company may, at its discretion, from time to time during the term of the sales agreement, sell up to a maximum of 14,018,692 million of its common shares through ATM issuances on the NASDAQ Stock Market, up to an aggregate amount of US $15 million. MLV will act as sales agent for any sales made under the ATM. The common shares will be sold at market prices prevailing at the time of the sale of common shares, and, as a result, prices may vary.

In connection with the execution of the ATM Sales Agreement with MLV, the Company will file with the United States Securities and Exchange Commission (the "SEC") a prospectus supplement to its shelf registration statement on Form F-3, which was declared effective by the SEC on March 28, 2014.

The shelf registration statement on Form F-3 and, when filed, the supplement thereto, will be available on the SEC's website (www.sec.gov). Alternatively, MLV will provide copies of these documents upon request by contacting MLV & Co. LLC, Attention: Randy Billhardt, 1251 Avenue of the Americas, 41st Floor, New York, NY 10020, or by calling 212-542-5882.

This press release does not and shall not constitute an offer to sell or the solicitation of an offer to buy any of the common shares, nor shall there be any sale of the common shares in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About Aeterna Zentaris Inc.

Aeterna Zentaris is a specialty biopharmaceutical company engaged in developing novel treatments in oncology and endocrinology. The Company's pipeline encompasses compounds at various stages of development. For more information please visit www.aezsinc.com.

©2012 PR Newswire. All Rights Reserved.

  • Health WatchMore>>

  • House approves VA health care overhaul

    House approves VA health care overhaul

    Wednesday, July 30 2014 9:12 PM EDT2014-07-31 01:12:40 GMT
    With a new Veterans Affairs secretary in place and an August recess looming, Congress is moving quickly to approve a compromise bill to refurbish the VA and improve veterans' health care.
    The House overwhelmingly approved a landmark bill Wednesday to help veterans avoid long waits for health care that have plagued the Veterans Affairs Department for years.
  • $1,000 Sovaldi now hepatitis treatment of choice

    $1,000 Sovaldi now hepatitis treatment of choice

    Wednesday, July 30 2014 8:58 PM EDT2014-07-31 00:58:45 GMT
    A $1,000-per-pill drug that insurers are reluctant to pay for has quickly become the treatment of choice for a liver-wasting viral disease that affects more than 3 million Americans.
    The price is sky-high, but so is demand. A new $1,000-per-pill drug has become the treatment of choice for Americans with hepatitis C, a liver-wasting disease that affects more than 3 million.
  • Deportations halted at New Mexico processing center

    Deportations halted at New Mexico processing center

    Deportations halted at New Mexico processing center

    Artesia, NM - Officials at an immigration processing center in new mexico announced they will be halting all deportations for the time being.
    Artesia, NM - Officials at an immigration processing center in new mexico announced they will be halting all deportations for the time being.